A recent study reviewed advances in lentiviral-vector technology that are reshaping gene-therapy delivery, highlighting improvements in tropism, payload capacity, and safety profiling. Authors Kaiser, Rouchka, and Smith detail manufacturing, integration risk mitigation, and evolving clinical applications where lentiviral platforms provide stable gene expression. The review underscores that lentiviral vectors remain a preferred choice for ex vivo cell therapies and for in vivo indications where integration is tolerated, while noting the regulatory and long-term surveillance considerations that accompany integrating vectors. Developers should weigh vector biology, payload design, and QC frameworks early in program planning.